NCT07799922 IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-05-20 with a primary completion date of 2027-12-31.

Brief Summary

This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of target-immunotherapy induction and have non-progressive disease will be enrolled. All patients must be considered unresectable or unable to tolerate surgical resection by MDT review and must provide written informed consent. Participants will be randomized 2:1. Forty patients will undergo open or percutaneous IRE followed by continuation of the original target-immunotherapy regimen; twenty patients will continue the original treatment regimen alone. OS, PFS, tumor response, QoL, safety, and postoperative outcomes will be observed.

Eligibility Criteria

Inclusion Criteria: * Age 18-75 years, any sex * Imaging-confirmed or histologically confirmed primary liver cancer/hepatocellular carcinoma (HCC) * After three cycles of target-immunotherapy induction, MDT review determines unresectable disease or inability to tolerate surgical resection * Willingness to receive standard conversion treatment * No prior palliative targeted immunotherapy or other systemic antitumor therapy * Maximum tumor diameter \<=5 cm and number of tumors \<=5 * No extrahepatic metastasis; portal vein tumor thrombus Vp1-3 * At least one measurable lesion according to RECIST 1.1 * Adequate organ and marrow function: hemoglobin \>=9.0 g/dL; neutrophils \>=1.5 x 10\^9/L; platelets \>=100 x 10\^9/L; TBIL \<=3 x ULN; AST and ALT \<=5.0 x ULN; serum creatinine \<=1.5 x ULN or CrCl \>60 mL/min by Cockcroft-Gault formula * ECOG Performance Status 0-1 * Expected survival of at least 3 months * Patients of childbearing potential and their partners agree to use contraception * Voluntary written informed consent Exclusion Criteria: * Refusal to receive systemic therapy or possible surgery * Metastasis to other sites, such as lymph nodes, peritoneum, lung, bone, or brain * History of other malignancies, except cured basal cell carcinoma of the skin or cervical carcinoma in situ * Severe uncontrolled comorbidities, including uncontrolled congestive heart failure (NYHA III/IV), unstable angina, poorly controlled arrhythmia, uncontrolled hypertension, active infection, uncontrolled diabetes, uncontrolled pleural effusion/pericardial effusion/ascites requiring drainage, severe portal hypertension or portal cavernoma on imaging, gastric outlet obstruction, or respiratory insufficiency requiring oxygen * Major surgery within 30 days before screening * EGFR monoclonal antibody or EGFR-TKI within 30 days before screening * Allergy to any drug or component used in this protocol * Known or self-reported HIV infection or chronic hepatitis B or hepatitis C * Unresolved toxicity \>=CTCAE grade 2 from prior treatment, except anemia, alopecia, skin pigmentation, or chemotherapy-induced neurotoxicity * Any other reason judged by the investigator to make participation inappropriate

Frequently Asked Questions

Related Trials